# EDGAR Filing Document

**Accession Number:** 0001703719
**File Stem:** 0001493152-25-026550
**Filing Date:** 2025-12
**Character Count:** 9189
**Document Hash:** fcc3605c41b3b2879119c87ea00911d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-026550.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001493152-25-026550

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-32172
- **FILM NUMBER:** 251554886

**BUSINESS ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929
- **BUSINESS PHONE:** (866) 594-5999

**MAIL ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rodrigues Dominic
- **CENTRAL INDEX KEY:** 0001703719

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 7327 OAK RIDGE HIGHWAY
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37931

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**PROVECTUS BIOPHARMACEUTICALS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**74373P108**

*(CUSIP Number)*

**Heather Raines**<br>800 S. Gay Street, Suite 1610<br>Knoxville TN 37929<br>(866) 594-5999

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74373P108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dominic Rodrigues** | Name of reporting person<br>**Dominic Rodrigues** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**24575060.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**64548.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**24575060.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**645489.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**25220549.00** | Aggregate amount beneficially owned by each reporting person<br>**25220549.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.67%** | Percent of class represented by amount in Row (11)<br>**5.67%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Sole voting and dispositive power includes 500 shares of common stock owned directly by the Reporting Person, 431,400 shares of common stock owned by the Reporting Person through a retirement plan, 10,764,400 shares of common stock issuable upon exercise of stock options that are currently exercisable, and 13,378,760 shares of common stock issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person.

(2) Shared voting and dispositive power includes 509,089 shares of common stock owned by the Reporting Person and spouse, 112,700 shares of common stock owned by the Reporting Person's spouse, and 23,700 shares of common stock held as custodian for children.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
PROVECTUS BIOPHARMACEUTICALS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929

**Item 4. Purpose of Transaction**

The Reporting Person acquired the securities for investment purposes. In his capacity as a director and executive officer of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances.

Except as described herein, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

The Reporting Person may, from time to time, purchase additional securities of the Issuer either in the open market or in privately-negotiated transactions, depending upon the Reporting Person's evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Person, general economic conditions, stock market conditions and other factors. Depending upon the factors noted above, the Reporting Person may also decide to hold or dispose of all or part of his investments in securities of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date of this Schedule 13D, the Reporting Person beneficially owns an aggregate of 25,220,549 shares of Common Stock, or 5.67% of the Issuer's outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule 13D are calculated based on a total of 420,279,879 shares of Common Stock outstanding as of December 2, 2025 plus (i) 13,378,760 shares of Common Stock issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person and (ii) 10,764,400 shares of Common Stock issuable upon exercise of stock options that are currently exercisable.

**(b)**
The Reporting Person has sole voting and dispositive power over 500 shares of Common Stock owned directly by the Reporting Person, 431,400 shares of Common Stock owned by the Reporting Person through a retirement plan, 13,378,760 shares of Common Stock issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, and 10,764,400 shares of Common Stock issuable upon exercise of stock options that are currently exercisable. The Reporting Person has shared voting and dispositive power over 509,089 shares of Common Stock owned by the Reporting Person and spouse, 112,700 shares of Common Stock owned by the Reporting Person's spouse, and 23,700 shares of Common Stock held as custodian for children.

**(c)**
On December 2, 2025, 5,382,200 stock options vested that were previously granted to the Reporting Person by the Issuer pursuant to a stock option award agreement.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On June 21, 2024, the Reporting Person and the Issuer entered into a conversion agreement providing for the forfeiture and redemption of 11,416,262 shares of Series D Convertible Preferred Stock in exchange for 1,141,626 shares of Series D-1 Convertible Preferred Stock.

On December 2, 2024, the Issuer granted the Reporting Person 16,146,600 stock options pursuant to a stock option award agreement. The stock options vest in three equal annual installments beginning on the grant date.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dominic Rodrigues

**Signature:** /s/ Dominic Rodrigues

**Name/Title:** Dominic Rodrigues, Vice-Chairman and President

**Date:** 12/08/2025